Introduction
Ramsay Hunt syndrome (RHS) is an infectious disease caused by the varicella zoster virus (VZV). 1 The main clinical symptoms are facial palsy, inner ear dysfunction, periauricular pain, and herpetiform vesicles on the pinna. J. Ramsay Hunt, in 1907, was the first author to describe the disease, which now represents the second most common cause of peripheral facial palsy. The incidence of RHS is 5 cases/100,000 people.
2
It affects mostly patients between the ages of 20 and 30, with no gender predilection. 1 Spontaneous remission of the facial palsy caused by VZV occurs only in a few cases -without proper treatment, only 20% achieve complete recovery.
3
The physiopathological mechanism is the reactivation of the VZV in the geniculate ganglion, with subsequent inflammation, edema, and compression of the VII cranial nerve.
2
Viral demyelination may also contribute to further damage of the nerve.
3,4 A viral prodrome or an upper respiratory tract infection might be the first symptoms, 5 evolving into severe pain in the pinna, acute facial hypotonia, and a herpetiform vesicular eruption on the pinna, external acoustic meatus, face, tongue, hard palate, neck, larynx, and oral mucosa.
Cochleovestibular impairment such as hypoacusis, tinnitus, and vertigo may occur. The involvement of other cranial nerves, such as V, IX, X, XI, and XII is rare. 1,6-8 Permanent facial deformity and other possible sequelae of RHS substantially impact patientś social life. Thus, early diagnosis and treatment of this clinical entity is essential to avoid such sequels.
6
Another clinical presentation of the disease is the "Ramsay Hunt syndrome sine herpete," characterized by peripheral facial paralysis without ear or mouth rash, and the presence of either a 4-fold rise in antibody to VZV or the detection of VZV DNA in skin, blood mononuclear cells, or middle ear fluid. Thus, some patients diagnosed with idiopathic facial palsy could be suffering from zoster sine herpete.
9,10
The objective of this study was to evaluate the prognosis of facial palsy in RHS after different treatments proposed in the literature, and to determine the best treatment option for these patients.
Materials and Methods
We performed a systematic review of the literature. The Ethics Committee of the Banco de Olhos de Sorocaba hospital approved this manuscript. We searched the LILACS, SciELO, and PUBMED databases from January to June 2015. The keywords used were: (Ramsay AND hunt) OR ("varicella") AND ("facial paralysis" OR ("facial" AND "paralysis") OR "facial paralysis" OR ("facial nerve" OR ("facial" AND "nerve"). Additional filters used were: period of publication: 1995-2014; human subjects; with abstracts available; Spanish, English, and Portuguese languages. We read the resulting studies in full, and the criteria for study selection were as follows: a) Inclusion Criteria ►Fig. 1 shows a flowchart of the decision process regarding the study selection.
Review of the Literature Results
The database search resulted in 259 studies. After reading all the resulting manuscripts in full by two of the authors, we selected 19 studies for appraisal, and included 13 in the quantitative analysis. The studies included a total of 882 patients with facial paralysis caused by RHS [1] [2] [3] [4] [5] [6] [7] [8] [11] [12] [13] [14] [15] [16] [17] (►Table 1). The duration of follow-up extended from 73 days to one year among the different studies.
Out of the 882 patients described in these studies, 829 (93.99%) had facial palsy grades III to VI on the HB scale. Following treatment, 621 out of the 882 (70.4%) achieved a score of I-II on the HB scale ("good prognosis").
Regarding the HB graduation before treatment, 53 (6%) were HB II, 150 (17%) HB III, 289 (32.7%) HB IV and 390 (44.2%) HB V or VI. After treatment, 621 (70.4%) achieved HB I or II and 261 (29.6%) achieved HB III, IV, or V. All of the patients were treated with steroids [1] [2] [3] [4] [5] [6] [7] [8] [11] [12] [13] [14] [15] [16] [17] ; however, Furuta et al 7 only
administered them to patients with facial palsy grades IV-VI at the initial examination. Antiviral agents were used in all patients, in exception of the 47 patients described in Kinishi et al's study.
14 These authors conducted a clinical trial in which 91 patients were treated with steroids (methylprednisolone, 500 mg on day 1, 250 mg on days 2 and 3, and 100 mg/d for 3 days thereafter), aciclovir (4000 mg/d for 7 days), dextran (500 mL/d for 7 days), vitamins B6 and B12 and peripheral vasodilators; another 43 patients received the same treatment but without the antiviral. Among the patients that received acyclovir, 85 (93.4%) achieved a good prognosis for facial palsy (HB I or II), compared with only 32 (68%) of the group that did not receive the antiviral agent (p < 0.05). Some authors treated patients with other drugs or therapies, such as dextran (500 mL for 7 days), 6,14 peripheral vasodilators, 6 adenosine triphosphate (ATP), 14 and vitamins B6 and B12.
14
The rate of complete recovery regarding the type of steroid associated with acyclovir varied among the studies. 1, 4, 7, 11, [14] [15] [16] [17] Regarding the patients treated with prednisone, 290 out of the 419 patients (69.2%) achieved a good prognosis; among the 192 patients treated with prednisolone, 118 (61.4%) achieved facial palsy HBI or II, versus 29 out of the 38 (76.3%) that received hydrocortisone, and 118 of the 145 (81.3%) patients treated with methylprednisolone. These results are presented in ►Table 2.
Some studies 6,16 compared the facial nerve recovery rate in patients with and without metabolic diseases. Patients with diabetes mellitus achieved worse recovery rates than patients without systemic diseases (p < 0.05). Patients older than 60 years with RHS had a delayed recovery of the facial nerve when compared with younger patients (p < 0.05), 6, 14 probably due to a less efficient cellular immune system, rather than a reduction in humoral immunity. 8 Nonetheless, the Uri et al 11 study did not evidence differences in the prognosis of facial palsy according to age and gender. Regarding the prognostic factors, the association between facial palsy and cochleovestibular impairment has worse prognosis than isolated facial nerve palsy (p ¼ 0.029).
11
Shim et al, 15 in a case-control study, observed that the recovery of the facial paralysis was worse when associated with impairment of other cranial nerves, regardless of the initial grade on the HB scale (p < 0.05).
Other pathologic changes include damage of the Corti organ and Scarpa ganglion, leading to hearing loss and vertigo. Although previous studies have reported a 10% recovery rate of patients with complete facial palsy even with correct treatment, 11 in our study, 51.4% of patients with facial palsy graded as HB V to VI treated with steroids plus antiviral agents achieved HB I or II. Treatment of RHS involves high doses of steroids and virostatic agents, especially acyclovir. The drugs, dosages, and period of treatment used by each author are described in ►Table 1. Even though the antiviral agents might theoretically cause several damaging effects, the number of the adverse effects on the selected studies was not significant.
3
Some authors treated patients with other drugs or therapies, such as dextran (500 mL for 7 days), 6,14 peripheral vasodilators, 6 adenosine triphosphate (ATP), 14 and vitamins B6 and B12.
14 However, many studies did not report the dosage, time of treatment, or period between the initial symptoms of facial palsy and treatment. Thus, it was difficult to define a treatment protocol and to compare the success of the treatments. For comparison purposes, "good prognosis" (adequate response to treatment) was considered when the HB grade increased to I or II after treatment. The percentage of patients with a good prognosis varied from 61.1% to 100% in the different studies. Regarding the different treatment regimens proposed, 68% of the patients with III to VI on the HB scale achieved a good prognosis when treated with steroids without the antiviral agent, 14 showed significant differences in the improvement of facial nerve function depending on the time elapsed between the onset of the symptoms and the start of treatment -the best results are achieved when treatment is introduced before the fifth day of the first symptoms. The same authors indicated that intravenous and oral drugs are equally efficient in terms of the recovery of the function of the facial nerve. They also reported that most of the patients with RHS did not require hospitalization.
15
Furuta et al 7 observed that patients with VZV in the oropharynx or with a viral load above 10,000 copies per 50 μL in the saliva had a worse recovery of the facial nerve function than patients with the isolated cutaneous form of the zoster infection (p ¼ 0.0019). Thus, the level of VZV DNA in the saliva reflects the kinetics of the viral reactivation in the facial nerve. Other parameters related to worse prognosis were lagophthalmus and dry eye (p < 0.05), which indicates the involvement of the large superficial petrosal nerve.
5
None of the selected studies refer to surgical management of the facial palsy in Ramsay Hunt syndrome. Bodénez et al, 19 however, proposed a flowchart regarding to the surgical approach -if the patient maintains complete facial palsy (HB V or VI) after the clinical treatment, the electromyography shows axonal loss higher than 95% and a time elapsed since the beginning of the facial palsy of 15 days, a surgical approach may be indicated.
Final Comments
Overall, patients with Ramsay Hunt syndrome achieved a high rate of complete recovery of the facial nerve function (70.4%) after the different proposed treatments. The combination of steroids and acyclovir reached better recovery rates than steroids in monotherapy. Dosage and period of treatment greatly varied among studies.
Clinical data such as age, associated metabolic diseases, impairment of the cochleovestibular, or other cranial nerves, oropharynx lesions, dry eye, and lagophthalmus must be assessed at the initial physical examination, since they suggest worse prognosis of the facial palsy secondary to Ramsay Hunt syndrome.
